Scholar Rock Holding Corp (SRRK)
NASDAQ:SRRK
SRRK Stock Chart & Stats
$43.08
-$0.51(-1.26%)
At close: 4:00 PM EST
$43.08
-$0.51(-1.26%)
Day’s Range― - ―
52-Week Range$22.71 - $49.82
Previous CloseN/A
Volume133.12K
Average Volume (3M)1.41M
Market Cap
$4.95B
Enterprise Value$5.43B
Total Cash (Recent Filing)$367.56M
Total Debt (Recent Filing)$108.92M
Price to Earnings (P/E)―
Beta1.69
Next Earnings
May 12, 2026EPS Estimate
-0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.88
Shares Outstanding114,883,095
10 Day Avg. Volume1,818,363
30 Day Avg. Volume1,407,345
Financial Highlights & Ratios
PEG Ratio-0.40
Price to Book (P/B)20.58
Price to Sales (P/S)0.00
P/FCF Ratio-16.81
Enterprise Value/Market Cap1.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.28K
Enterprise Value/Ebitda-14.71
Forecast
1Y Price Target
$58.10Price Target Upside34.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-3.14
Revenue Forecast (FY)$19.72M
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyPhase 3 SAPPHIRE data demonstrated statistically significant and clinically meaningful motor function improvements on top of standard therapies, supporting apitegromab's potential to become the first muscle-targeted treatment and to drive strong physician adoption.
Commercial Preparedness And FinancingExpanded commercial preparations, including an active field team, a broad specialty pharmacy and home infusion nurse network, plus a sizable non-dilutive debt facility to fund launch activities, enhance readiness to support early patient access and uptake.
Competitive LandscapeDiscontinuation of a late-stage anti-myostatin competitor that lacked meaningful differentiation reinforces apitegromab's position as the leading muscle-building therapy and increases the likelihood of capturing substantial market share.
Bears Say
Manufacturing And Regulatory UncertaintySite observations at a key contract fill-finish facility have created regulatory hurdles and leave uncertainty about whether remediation will be deemed sufficient or how the resubmitted application will be classified for review, which could delay or complicate approval.
Market Sentiment And Stock VolatilityNotable short interest and historical share volatility reflect investor skepticism about near-term prospects and increase the risk of amplified downside moves if challenges persist.
Reimbursement RiskInitial insurance coverage may be limited until a specific billing or reimbursement code is established, which could slow early patient access and constrain initial sales momentum.
Scholar Rock Holding News
SRRK FAQ
What was Scholar Rock Holding Corp’s price range in the past 12 months?
Scholar Rock Holding Corp lowest stock price was $22.71 and its highest was $49.82 in the past 12 months.
What is Scholar Rock Holding Corp’s market cap?
Scholar Rock Holding Corp’s market cap is $4.95B.
When is Scholar Rock Holding Corp’s upcoming earnings report date?
Scholar Rock Holding Corp’s upcoming earnings report date is May 12, 2026 which is in 41 days.
How were Scholar Rock Holding Corp’s earnings last quarter?
Scholar Rock Holding Corp released its earnings results on Mar 03, 2026. The company reported -$0.88 earnings per share for the quarter, beating the consensus estimate of -$0.89 by $0.01.
Is Scholar Rock Holding Corp overvalued?
According to Wall Street analysts Scholar Rock Holding Corp’s price is currently Undervalued.
Does Scholar Rock Holding Corp pay dividends?
Scholar Rock Holding Corp does not currently pay dividends.
What is Scholar Rock Holding Corp’s EPS estimate?
Scholar Rock Holding Corp’s EPS estimate is -0.81.
How many shares outstanding does Scholar Rock Holding Corp have?
Scholar Rock Holding Corp has 114,883,095 shares outstanding.
What happened to Scholar Rock Holding Corp’s price movement after its last earnings report?
Scholar Rock Holding Corp reported an EPS of -$0.88 in its last earnings report, beating expectations of -$0.89. Following the earnings report the stock price went up 1.909%.
Which hedge fund is a major shareholder of Scholar Rock Holding Corp?
Currently, no hedge funds are holding shares in SRRK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Scholar Rock Holding Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$58.10 (34.87% Upside)
$58.10 (34.87% Upside)
Blogger Sentiment
Bullish
SRRK Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $11.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.4%
Last 30 Days ▼ 0.8%
Last 30 Days ▼ 0.8%
News Sentiment
Very Bullish
Bullish news 92%
Bearish news 8%
Bearish news 8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.69%
12-Months-Change
Fundamentals
Return on Equity
-145.91%
Trailing 12-Months
Asset Growth
-14.88%
Trailing 12-Months
Company Description
Scholar Rock Holding Corp
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
SRRK Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong forward momentum: focused regulatory engagement with FDA (including a field visit), readiness to resubmit the BLA following an expected reinspection, an advancing clinical pipeline (multiple studies including FSHD and SRK‑439), active commercial build (field team, specialty pharmacy and home infusion networks), and materially strengthened financing optionality (warrant proceeds plus a $550M debt facility). The key negative is continued regulatory and manufacturing risk tied to Catalent’s remediation status, plus high pre‑launch operating spend and potential payer access timing issues. On balance, the highlights—substantive regulatory engagement, concrete mitigation steps (second fill‑finish facility), robust pipeline progress, commercial preparedness, and improved liquidity—outweigh the remaining execution risks.View all SRRK earnings summariesSRRK Stock 12 Month Forecast
Average Price Target
$58.10
▲(34.87% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Viking Therapeutics
―
Xenon
―
Immunovant
―
NewAmsterdam Pharma Company
―
Ownership Overview
Currently, No data available
---